US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soligenix, Inc.

1.87

+0.03001.63%

Volume:30.25K

Turnover:54.98K

Market Cap:5.90M

PE:-0.31

High:1.89

Open:1.84

Low:1.78

Close:1.84

Loading ...

Overview Company News Filings

SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…

Zacks Small Cap Research

IBN Initiates Coverage of Soligenix Inc.

BRIEF-Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

THOMSON REUTERS

Press Release: Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Soligenix Inc expected to post a loss of 95 cents a share - Earnings Preview

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

SNGX: Presentation Highlights HyBryte Potential in CTCL…

Zacks Small Cap Research

Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison

THOMSON REUTERS

Soligenix’s HyBryte shows efficacy in T-cell lymphoma trial

BRIEF-HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Hybryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

THOMSON REUTERS

EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year

SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…

Zacks Small Cap Research

Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma

MT Newswires Live

Soligenix initiates confirmatory Phase 3 trial of HyBryte

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma

THOMSON REUTERS

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":1.87,"timestamp":1744056000000,"preClose":1.84,"halted":0,"volume":30253,"delay":0,"floatShares":3154900,"shares":3155603,"eps":-5.940807,"marketStatus":"Pre-Market Trading","change":0.03,"latestTime":"04-08 05:57:25 EDT","open":1.84,"high":1.89,"low":1.78,"amount":54981.5420242,"amplitude":0.059783,"askPrice":2.23,"askSize":100,"bidPrice":1.63,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.940807,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744119000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.87,"postHourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.87,"latestTime":"17:43 EDT","volume":1357,"amount":2512.1524,"timestamp":1744062235202},"volumeRatio":1.3082830866116972},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":3154900,"roa":"-62.88%","roe":"-248.97%","lyrEps":-12.66451,"volumeRatio":1.3082830866116972,"shares":3155603,"dividePrice":0,"high":1.89,"amplitude":0.059783,"preClose":1.84,"low":1.78,"week52Low":1.68,"pbRate":"1.43","psRate":"49.43","week52High":14.9184,"institutionHeld":0.0042,"latestPrice":1.87,"eps":-5.940807,"divideRate":0,"volume":30253,"delay":0,"ttmEps":-5.940807,"open":1.84,"prevYearClose":2.695,"prevWeekClose":1.84,"prevMonthClose":2.15,"prevQuarterClose":2.15,"fiveDayClose":2.15,"twentyDayClose":2.26,"sixtyDayClose":3.27},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522380305","title":"SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…","url":"https://stock-news.laohu8.com/highlight/detail?id=2522380305","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522380305?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"CiVax Booster Enhances Protection from COVID-19 in NHPs. On March 25, 2025, Soligenix, Inc.  announced a publication that includes results from a prime-boost study in non-human primates  that showed the use of CiVax, the company’s thermostabilized subunit vaccine against SARS-CoV-2, following vaccination with a primary adenovirus vaccine  resulted in a robust immune response against SARS-CoV-2 variants.The ThermoVax platform has a number of advantages over other vaccine platforms, including its use of protein subunits without the need for strict cold-storage requirements. These most recent results show that CiVax can induce a rapid, robust immune response against SARS-CoV-2 variants even when administered after another primary vaccine series. Combined with a proven vaccine technology, these results show the company’s vaccine platform could be utilized for current threats as well as those that may emerge in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-preclinical-data-shows-civax-121500311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","SNGX","BK4139"],"gpt_icon":0},{"id":"2522075375","title":"IBN Initiates Coverage of Soligenix Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075375","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075375?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:30","pubTimestamp":1742905800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, March 25, 2025  -- via IBN – Soligenix Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts.Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte  as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma . With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin  into psori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibn-initiates-coverage-soligenix-inc-123000018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868838027.USD","LU1102505762.USD","LU0066902890.USD","LU1868837565.USD","SNGX","LU0261950470.USD","LU0828237940.HKD","LU1481012133.USD","BK4207","BK4585","LU0143863784.USD","LU0143863198.USD","IBN","IE00B7N09G41.SGD","LU0048575426.USD","BK4139","LU0181495838.USD","IE00BYTNYM70.SGD","IDR","LU0823038988.USD","LU0823039010.USD","BK4548","LU0251143458.SGD","BK4588","DBP","LU1102505929.USD","BK4523","LU0531971678.HKD","IE00B0JY6M65.USD","LU1868837722.USD","LU0164881194.USD","BK4535","SG9999004220.SGD","LU0264410563.USD","BK4168"],"gpt_icon":0},{"id":"2522299180","title":"BRIEF-Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2522299180","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522299180?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:35","pubTimestamp":1742902554,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25 (Reuters) - Soligenix Inc SNGX.O:SOLIGENIX ANNOUNCES PUBLICATION DEMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q80B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2521285354","title":"Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521285354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521285354?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:23","pubTimestamp":1742559826,"startTime":"0","endTime":"0","summary":"Soligenix Inc reports results for the quarter ended December 31 - Earnings SummarySoligenix Inc SNGX.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended December 31, higher ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2521407754","title":"Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521407754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521407754?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA2DMC9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2521072414","title":"Press Release: Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521072414","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521072414?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556600,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024.Dr. Schaber continued, \"With approximately $7.8 million in cash at December 31, 2024, we are committed to disciplined resource allocation to achieve our strategic goals. While this cash balance provides operating runway through 2025, we continue to evaluate all strategic options, including partnership, merger and acquisition, government grants, and potential financing opportunities to advance our late-stage pipeline and the Company.\". with early-stage CTCL. To view this press release, please click here.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4168","IDR","BK4232","BK4139","R","03160","BK4604","BK4022","TM","BK4555","MAB","BK4588","BK4099","SNGX","BK4585"],"gpt_icon":0},{"id":"2519010978","title":"Soligenix Inc  expected to post a loss of 95 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519010978","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519010978?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:12","pubTimestamp":1741957926,"startTime":"0","endTime":"0","summary":"Soligenix Inc  expected to post a loss of95cents a share - Earnings Preview Soligenix Inc SNGX.OQ SNGX.O is expected to show a rise in quarterly revenue when it reports  results on March 17 (estimated","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX18F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2517086154","title":"HyBryte™ Treatment Studies Presented at Two Medical Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2517086154","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517086154?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy. Conference: USCLC Workshop \"Cutaneous Lymphomas in Special Populations\" March 6, Orlando, Florida. The official conference program can be found here.Presentation Title: Topical hypericin ointment photodynamic therapy for early stage mycosis fungoides/CTCL – a Phase 2 real world investigator-initiated study presented by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania.presented by Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research and chief medical editor at Practical Dermatology. The official conference program can be found here.These presentations incorporate the Company's findings in recentsupportive studies which have demonstrated the utility of longer treatment times, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hybryte-treatment-studies-presented-two-123000102.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hybryte-treatment-studies-presented-two-123000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BSA","IDR","SNGX","BK4168"],"gpt_icon":0},{"id":"2514067427","title":"SNGX: Presentation Highlights HyBryte Potential in CTCL…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067427","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067427?lang=en_us&edition=fundamental","pubTime":"2025-02-25 00:02","pubTimestamp":1740412920,"startTime":"0","endTime":"0","summary":"In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on “Off-Label Uses of PDT” . Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, a member of Soligenix’s  scientific advisory board, and was a participating investigator in the Phase 3 HyBryte trial. During his presentation, Dr. Bhatia discussed the efficacy results from multiple studies of HyBryte along with results from studies examining Valchlor , also known as nitrogen mustard , which is indicated for the treatment of Stage IA and IB mycosis fungoides-type cutaneous T cell lymphoma . Valchlor was approved based in part on the results of a Phase 3 trial in which it was compared to a compounded 0.02% mechlorethamine ointment . The study was successful and showed that Valchlor was superior to the ointment .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-presentation-highlights-hybryte-potential-160200810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4021","SNGX","NM"],"gpt_icon":0},{"id":"2510859400","title":"Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859400?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:33","pubTimestamp":1739190790,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2503524270","title":"Soligenix’s HyBryte shows efficacy in T-cell lymphoma trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503524270","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503524270?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:35","pubTimestamp":1736858116,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenixs-hybryte-shows-efficacy-in-t-cell-lymphoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenixs-hybryte-shows-efficacy-in-t-cell-lymphoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2503241045","title":"BRIEF-HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2503241045","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503241045?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:34","pubTimestamp":1736858043,"startTime":"0","endTime":"0","summary":"BRIEF-HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJan 14 (Reuters) - Soligenix Inc SNGX.O:HYBRYTE EXPANDED TREATMENT CONTINUES TO DEMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2503524929","title":"Hybryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2503524929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503524929?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:30","pubTimestamp":1736857827,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2503655520","title":"EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2503655520","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503655520?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:15","pubTimestamp":1736856917,"startTime":"0","endTime":"0","summary":"On Tuesday, Soligenix Inc.  announced an interim update on the open-label, investigator-initiated study  evaluating extended HyBryte  treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma , a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection.Cutaneous T-cell lymphomais a groupof rare blood cancersthat affects the skin.Nine patients have been enrolled and treated with HyBryte over up to 54 weeks.Also Read: Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels. Patients have responded positively to HyBryte therapy, with over 70%  already achieving \"Treatment Success.\". Treatment Success is predefined in the study's protocol as a greater than or equal to 50% improvement in the cumulative mCAILS  score compared to the baseline.Three of the five Treatment Successes were achieved within the first 12 weeks of treatment, with two patients achieving a \"complete response\" by 18 weeks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-soligenixs-cancer-candidate-shows-121517231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2503503280","title":"SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…","url":"https://stock-news.laohu8.com/highlight/detail?id=2503503280","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503503280?lang=en_us&edition=fundamental","pubTime":"2025-01-14 18:09","pubTimestamp":1736849340,"startTime":"0","endTime":"0","summary":"On January 14, 2025, Soligenix, Inc.  announced additional positive data from the open-label, investigator-initiated study  of HyBryte  for patients with cutaneous T cell lymphoma  for up to 12 months. During the study patients are treated twice a week and the protocol allows for the potential transition to a “real-world” setting with at-home use. The trial is being sponsored by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania and is being funded by a $2.6 million Orphan Products Development Grant from the FDA.DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing rese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-additional-positive-outcomes-investigator-100900289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2491693787","title":"Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693787","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693787?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:05","pubTimestamp":1734354345,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) said Monday it has begun patient enrollment for its phase 3 study of its experimental therapy, HyBryte, to treat cutaneous T-cell lymphoma or CTCL.The company said the study builds on previous phase 3 results and additional supportive research.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2491660037","title":"Soligenix initiates confirmatory Phase 3 trial of HyBryte","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660037?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:35","pubTimestamp":1734352506,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenix-initiates-confirmatory-phase-3-trial-of-hybryte?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenix-initiates-confirmatory-phase-3-trial-of-hybryte?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2491660110","title":"Soligenix Initiates Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660110?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:30","pubTimestamp":1734352204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUA5X5QRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2491698224","title":"EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491698224","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491698224?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:15","pubTimestamp":1734351316,"startTime":"0","endTime":"0","summary":"On Monday, Soligenix, Inc.  said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte  for cutaneous T-cell lymphoma .The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3  study, as well as a recent comparative study  and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial.Also Read: Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels. The FLASH2 study is expected to enroll patients in the U.S. and Europe, and a formal interim analysis is anticipated early in 2026.The company looks forward to providing periodic updates on the trial's progress in 2025. FLASH2 will enroll approximately 80 subjects with early-stage CTCL, a group of rare blood cancers that affect the skin.The extended treatment for a continuous 18 weeks in a single cycle is expected to statistically demonstrate the effect of HyBryte over a more prolonged, \"r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1N9wJ_JuKqJJT7b.NQp62A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b6f51e37681f48ad3ecc673c5195f0db","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1N9wJ_JuKqJJT7b.NQp62A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b6f51e37681f48ad3ecc673c5195f0db"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-soligenix-starts-confirmatory-stage-121516113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SNGX","SSI"],"gpt_icon":0},{"id":"2488976817","title":"Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2488976817","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488976817?lang=en_us&edition=fundamental","pubTime":"2024-12-04 04:45","pubTimestamp":1733258700,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing.Participants and those unable to attend can now access the presentations at their convenience:. Click the Presentation Links Below To Access Presentations:. Forum Energy Tech Presentation Investor Summit November 21. To learn more and gain insights from the event, visit the Investor Summit Group website and explore valuable content shared by industry experts.We believe in connecting investors with the best microcap and smallcap companies. We are an independent company dedicated to fostering a unique and valuable ecosystem where investors can discover promising opportunities. Our carefully curated events feature companies with strong fundamentals and growth potential,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MyZHbHdNhq61VfcrOcPIIA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/7cd0e09f71d981c181d1161115c223c6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MyZHbHdNhq61VfcrOcPIIA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/7cd0e09f71d981c181d1161115c223c6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/winter-2024-investor-summit-virtual-204500775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4179","IMUX","BLGO","NQmain","BK4164","CPSH","QLD","TQQQ","HLRTF",".IXIC","ACON","PLUR","MNQmain","NMTC","BK4023","BK4167","BK4148","SPGC","TGCB","LMFA","BK4096","SQQQ","BK4211","ULY","AUUDW","ACFN","SMMF","SOTK","SNGX","AUUD","IMRN","BK4157","ACONW","BK4182","BK4139","PSQ","BK4213","BK4190","FET","OESX","BK4109","QID","BK4082"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14},{"market":"US","date":"2024-11-08","symbol":"SNGX","fiscalQuarterEnding":"2024/09","expectedEps":-1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2024-08-09","symbol":"SNGX","fiscalQuarterEnding":"2024/06","expectedEps":-2.11,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-1.31},{"market":"US","date":"2024-06-06","symbol":"SNGX","defaultRemindTime":1717680600000,"type":"split","dateTimestamp":1717646400000,"forFactor":16,"toFactor":1,"ratio":16},{"market":"US","date":"2024-05-10","symbol":"SNGX","fiscalQuarterEnding":"2024/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2025-04-07","current":-0.702384,"percent":0.826299,"low":-5.464746,"twenty":-3.374947,"median":-1.751227,"eighty":-0.788146,"high":-0.277411,"avg":-1.999023,"sd":1.259219,"marketCap":5806309},"quantilePoints":[{"date":"2020-04-09","current":-3.995333,"twenty":-3.707646,"median":-2.965739,"eighty":-2.107674,"marketCap":37378704},{"date":"2020-04-17","current":-4.022887,"twenty":-3.712662,"median":-2.965739,"eighty":-2.106354,"marketCap":37636488},{"date":"2020-04-24","current":-3.885117,"twenty":-3.712662,"median":-2.965739,"eighty":-2.106354,"marketCap":36347567},{"date":"2020-05-01","current":-4.215765,"twenty":-3.71974,"median":-2.965739,"eighty":-2.106354,"marketCap":39440977},{"date":"2020-05-08","current":-4.491305,"twenty":-3.744873,"median":-2.965739,"eighty":-2.106354,"marketCap":42018818},{"date":"2020-05-15","current":-2.72763,"twenty":-3.745836,"median":-2.963367,"eighty":-2.106354,"marketCap":41725374},{"date":"2020-05-22","current":-3.648423,"twenty":-3.745836,"median":-2.957629,"eighty":-2.106354,"marketCap":55811010},{"date":"2020-05-29","current":-3.318327,"twenty":-3.745836,"median":-2.957629,"eighty":-2.106354,"marketCap":50761441},{"date":"2020-06-05","current":-3.683169,"twenty":-3.745836,"median":-2.957629,"eighty":-2.106354,"marketCap":56342543},{"date":"2020-06-12","current":-3.300954,"twenty":-3.747347,"median":-2.957629,"eighty":-2.106354,"marketCap":50495674},{"date":"2020-06-19","current":-3.075099,"twenty":-3.747347,"median":-2.957629,"eighty":-2.106354,"marketCap":47040707},{"date":"2020-06-26","current":-3.631049,"twenty":-3.744873,"median":-2.957629,"eighty":-2.106354,"marketCap":55545243},{"date":"2020-07-02","current":-3.405194,"twenty":-3.729793,"median":-2.957629,"eighty":-2.106354,"marketCap":52090276},{"date":"2020-07-10","current":-3.526808,"twenty":-3.712662,"median":-2.957629,"eighty":-2.106354,"marketCap":53950642},{"date":"2020-07-17","current":-4.183339,"twenty":-3.710161,"median":-2.957629,"eighty":-2.106354,"marketCap":63993787},{"date":"2020-07-24","current":-4.164923,"twenty":-3.710161,"median":-2.957629,"eighty":-2.106354,"marketCap":63712077},{"date":"2020-07-31","current":-4.202786,"twenty":-3.71974,"median":-2.957629,"eighty":-2.106354,"marketCap":64291278},{"date":"2020-08-07","current":-4.278512,"twenty":-3.73529,"median":-2.958383,"eighty":-2.106354,"marketCap":65449680},{"date":"2020-08-14","current":-3.798616,"twenty":-3.745836,"median":-2.963367,"eighty":-2.106354,"marketCap":60589987},{"date":"2020-08-21","current":-4.041878,"twenty":-3.787557,"median":-2.963367,"eighty":-2.106354,"marketCap":64470134},{"date":"2020-08-28","current":-3.686342,"twenty":-3.798616,"median":-2.963367,"eighty":-2.106354,"marketCap":58799151},{"date":"2020-09-04","current":-3.368231,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":53725112},{"date":"2020-09-11","current":-3.555355,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":56709840},{"date":"2020-09-18","current":-3.742479,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":59694570},{"date":"2020-09-25","current":-3.181107,"twenty":-3.792424,"median":-2.965739,"eighty":-2.107674,"marketCap":50740384},{"date":"2020-10-02","current":-3.255957,"twenty":-3.792424,"median":-2.974005,"eighty":-2.107674,"marketCap":51934274},{"date":"2020-10-09","current":-3.349519,"twenty":-3.792424,"median":-2.993101,"eighty":-2.107674,"marketCap":53426639},{"date":"2020-10-16","current":-3.349519,"twenty":-3.792424,"median":-2.996669,"eighty":-2.107674,"marketCap":53426639},{"date":"2020-10-23","current":-3.405656,"twenty":-3.792424,"median":-3.016006,"eighty":-2.107674,"marketCap":54322058},{"date":"2020-10-30","current":-3.181107,"twenty":-3.792424,"median":-3.02874,"eighty":-2.107674,"marketCap":50740384},{"date":"2020-11-06","current":-3.068833,"twenty":-3.792424,"median":-3.03163,"eighty":-2.107674,"marketCap":48949546},{"date":"2020-11-13","current":-3.576924,"twenty":-3.792424,"median":-3.032343,"eighty":-2.107674,"marketCap":53725112},{"date":"2020-11-20","current":-4.371797,"twenty":-3.807236,"median":-3.032343,"eighty":-2.107674,"marketCap":65664026},{"date":"2020-11-27","current":-4.332053,"twenty":-3.808915,"median":-3.032343,"eighty":-2.107674,"marketCap":65067080},{"date":"2020-12-04","current":-4.967951,"twenty":-3.822057,"median":-3.032343,"eighty":-2.113513,"marketCap":74618212},{"date":"2020-12-11","current":-4.570515,"twenty":-3.833505,"median":-3.035911,"eighty":-2.115839,"marketCap":68648754},{"date":"2020-12-18","current":-5.325643,"twenty":-3.84402,"median":-3.041386,"eighty":-2.116451,"marketCap":79990722},{"date":"2020-12-24","current":-2.662821,"twenty":-3.835838,"median":-3.035911,"eighty":-2.116451,"marketCap":39995360},{"date":"2020-12-31","current":-2.543591,"twenty":-3.825781,"median":-3.032517,"eighty":-2.116451,"marketCap":38204524},{"date":"2021-01-08","current":-2.821796,"twenty":-3.820118,"median":-3.031986,"eighty":-2.116451,"marketCap":42383144},{"date":"2021-01-15","current":-2.997624,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":45024063},{"date":"2021-01-22","current":-3.605533,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":54154817},{"date":"2021-01-29","current":-3.249173,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":48802306},{"date":"2021-02-05","current":-3.458797,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-02-12","current":-4.485954,"twenty":-3.822137,"median":-3.02874,"eighty":-2.116451,"marketCap":67378666},{"date":"2021-02-19","current":-3.982857,"twenty":-3.833505,"median":-3.030551,"eighty":-2.116451,"marketCap":59822181},{"date":"2021-02-26","current":-3.458797,"twenty":-3.833505,"median":-3.03163,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-03-05","current":-3.207248,"twenty":-3.835264,"median":-3.031519,"eighty":-2.11619,"marketCap":48172598},{"date":"2021-03-12","current":-3.75227,"twenty":-3.835264,"median":-3.03243,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-19","current":-3.75227,"twenty":-3.83612,"median":-3.040991,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-26","current":-3.270135,"twenty":-3.835838,"median":-3.042299,"eighty":-2.116451,"marketCap":49117159},{"date":"2021-04-01","current":-3.529516,"twenty":-3.826467,"median":-3.042299,"eighty":-2.116451,"marketCap":62431916},{"date":"2021-04-09","current":-3.41639,"twenty":-3.822157,"median":-3.042299,"eighty":-2.11619,"marketCap":60430892},{"date":"2021-04-16","current":-2.963888,"twenty":-3.822157,"median":-3.041843,"eighty":-2.11619,"marketCap":52426802},{"date":"2021-04-23","current":-3.212764,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":56829052},{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-07","current":-0.702384,"twenty":-3.374947,"median":-1.751227,"eighty":-0.788146,"marketCap":5806309}],"updateTime":1744102267191}}}